Outlook Therapeutics, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 46 of Outlook Therapeutics, Inc.'s SEC filings and found 20 warrant series, 1 convertible, 2 ATM programs, 7 shelf registrations and 4 completed offerings on file for OTLK. The latest dilution event on file is an offering on Aug 14, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
OTLK
Going-concern warning and cash crunch
Snapshot
Outlook Therapeutics is a tiny biotech with a $35 million market cap that is burning through its cash reserves. The company reported $1.4 million in revenue for FY 2025 but lost $62.4 million in net income, driven by heavy research and development spending of $27.2 billion (likely a data error in the source, but clearly massive relative to revenue) and operating losses. It holds only $8.1 million in cash against $30.2 million in debt, leaving a cash runway of just 1.1 months at current burn rates.
What's Happening Right Now
- : Outlook announced a $5.0 million registered direct offering to its largest stockholder, GMS Ventures, at $0.5855 per share to fund working capital.
- : The FDA granted Outlook's appeal regarding its lead drug LYTENAVA, reversing a previous rejection and clearing the path for a resubmission in June 2026.
- : The company reported substantial doubt about its ability to continue as a going concern, citing insufficient cash to fund operations for the next 12 months.
